Abstract
Rationale
Mice of many 129 substrains respond to environmental novelty with behavioural suppression and high levels of anxiety-like behaviour. Although resistant to conventional anxiolytics, this behavioural phenotype may involve stress-induced release of endogenous opioids.
Objectives
To assess the effects of opioid receptor blockade on behavioural reactions to novelty stress in a chlordiazepoxide-resistant 129 substrain.
Materials and methods
Experiment 1 contrasted the effects of the broad-spectrum opioid receptor antagonist naloxone (1.0–10.0 mg/kg) in C57BL/6JOlaHsd and 129S2/SvHsd mice exposed to the elevated plus-maze. Experiments 2–4 examined the responses of 129S2/SvHsd mice to the μ-selective opioid receptor antagonist β-funaltrexamine (2.5–10.0 mg/kg), the δ-selective antagonist naltrindole (2.5–10.0 mg/kg) and the κ-selective antagonist nor-binaltorphimine (2.5–5.0 mg/kg).
Results
129 mice displayed higher levels of anxiety-like behaviour and lower levels of general exploration relative to their C57 counterparts. Although naloxone failed to alter the behaviour of C57 mice, both doses of this antagonist produced behaviourally selective reductions in open-arm avoidance in 129 mice. Surprisingly, none of the more selective opioid receptor antagonists replicated this effect of naloxone: β-funaltrexamine was devoid of behavioural activity, naltrindole suppressed rearing (all doses) and increased immobility (10 mg/kg), while nor-binaltorphimine (5 mg/kg) nonspecifically increased percent open arm entries.
Conclusions
Recent evidence suggests differential involvement of opioid receptor subtypes in the anxiolytic efficacy of diverse compounds including conventional benzodiazepines. The insensitivity of 129 mice to the anxiolytic action of chlordiazepoxide, coupled with their atypical anxiolytic response to naloxone (but not more selective opioid receptor antagonists), suggests an abnormality in anxiety-related neurocircuitry involving opioid-GABA interactions.
Similar content being viewed by others
References
Agmo A, Belzung C (1998) The role of subtypes of the opioid receptor in the anxiolytic action of chlordiazepoxide. Neuropharmacology 37:223–232
Agmo A, Galvan A, Heredia A, Morales M (1995) Naloxone blocks the antianxiety but not the motor effects of benzodiazepines and pentobarbital: experimental studies and literature review. Psychopharmacology 120:186–194
Agmo A, Belzung C, Deloire X, Grassin M, Lewis S (1999) Blockade of anxiolytic-like actions of chlordiazepoxide by naloxone in the elevated plus-maze: comparisons between Swiss, C57BL/6 and BALB/c mice. Psychobiology 27:105–113
Anisman H, Hayley S, Kelly O, Borowski T, Merlai Z (2001) Psychogenic, neurogenic, and systemic stressor effects on plasma corticosterone and behavior: mouse strain-dependent outcomes. Behav Neurosci 115:443–454
Baldwin DS, Anderson IM, Nutt DJ, Bandelow B, Bond A, Davidson JRT, den Boer JA, Fineberg NA, Knapp M, Scott J, Wittchen H-U (2005) Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 19:567–596
Balerio GN, Aso E, Maldonado R (2005) Involvement of the opioid system in the effects induced by nicotine on anxiety-like behaviour in mice. Psychopharmacology 181:260–269
Baran A, Shuster L, Eleftheriou BE, Bailey DW (1975) Opiate receptor binding in mice: genetic differences. Life Sci 17:633–638
Belzung C, Agmo A (1997a) Naloxone blocks anxiolytic-like effects of benzodiazepines in Swiss but not BALB/c mice. Psychopharmacology 132:195–201
Belzung C, Agmo A (1997b) Naloxone potentiates the effects of subeffective doses of anxiolytic agents in mice. Eur J Pharmacol 323:133–136
Belzung C, Barreau S, Agmo A (2000) Naloxone potentiates anxiolytic-like actions of diazepam, pentobarbital and meprobamate but not those of Ro19-8022 in the rat. Eur J Pharmacol 394:289–294
Belzung C, Griebel G (2001) Measuring normal and pathological anxiety-like behaviour in mice: a review. Behav Brain Res 125:141–149
Berrendero F, Maldonado R (2002) Involvement of the opioid system in the anxiolytic-like effects induced by Δ9-tetrahydrocannabinol. Psychopharmacology 163:111–117
Bilkei-Gorzo A, Racz I, Michel K, Zimmer A, Klingmuller D, Zimmer A (2004) Behavioral phenotype of pre-proenkephalin-deficient mice on diverse genetic backgrounds. Psychopharmacology 176:343–352
Bolivar VJ, Caldarone BJ, Reilly AA, Flaherty L (2000) Habituation of activity in an open field: a survey of inbred strains and F1 hybrids. Behav Genet 30:285–293
Bouwknecht JA, Paylor RE (2002) Behavioral and physiological mouse assays for anxiety: a survey in nine mouse strains. Behav Brain Res 136:489–501
Bouwknecht JA, van der Gugten J, Groenink L, Olivier B, Paylor RE (2004) Behavioral and physiological mouse models for anxiety: effects of flesinoxan in 129S6/SvEvTac and C57BL/6J mice. Eur J Pharmacol 494:45–53
Carter TA, Del Rio JA, Greenhall JA, Latronica ML, Lockhart DJ, Barlow C (2001) Chipping away at complex behavior: transcriptome/phenotype correlations in the mouse brain. Physiol Behav 73:849–857
Clement Y, Calatayud F, Belzung C (2002) Genetic basis of anxiety-like behaviour: a critical review. Brain Res Bull 57:57–71
Cohen GA, Doze VA, Madison DV (1992) Opioid inhibition of GABA release from presynaptic terminals of rat hippocampal interneurons. Neuron 9:325–335
Contet C, Rawlins JNP, Deacon RMJ (2001) A comparison of 129S2/SvHsd and C57BL/6JOlaHsd mice on a test battery assessing sensorimotor, affective and cognitive behaviours: implications for the study of genetically modified mice. Behav Brain Res 124:33–46
Cook MN, Bolivar VJ, McFadyen MP, Flaherty L (2002) Behavioral differences among 129 substrains: implications for knockout and transgenic mice. Behav Neurosci 116:600–611
Crabbe JC, Wahlsten D, Dudek BC (1999) Genetics of mouse behavior: interactions with laboratory environment. Science 284:1670–1672
Crawley JN (2000). What’s wrong with my mouse? Behavioral phenotyping of transgenic and knockout mice. Wiley-Liss, New York
Crawley JN, Belknap JK, Collins A, Crabbe JC, Frankel W, Henderson N, Hitzemann RJ, Maxson SC, Miner LL, Silva AJ, Wehner JM, Wynshaw-Boris A, Paylor R (1997) Behavioral phenotypes of inbred mouse strains: implications and recommendations for molecular studies. Psychopharmacology 132:107–124
Endoh T, Matsuura H, Tanaka C, Nagase H (1992) Nor-binaltorphimine: a potent and selective κ-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther 316:30–42
Filliol D, Ghozland S, Chluba J, Martin M, Matthes HWD, Simonin F, Befort K, Gaveriaux-Ruff C, Dierich A, LeMeur M, Valverde O, Maldonado R, Kieffer B (2000) Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195–200
Frussa-Filho R, Barbosa-Junior H, Silva RH, Da Cunha C, Mello CF (1999) Naltrexone potentiates the anxiolytic effects of chlordiazepoxide in rats exposed to novel environments. Psychopharmacology 147:168–173
Gerlai R (1996) Gene-targeting studies of mammalian behavior: is it the mutation or the genetic background? Trends Neurosci 19:177–178
Gerlai R (2001) Gene targeting: technical confounds and potential solutions in behavioral brain research. Behav Brain Res 125:13–21
Goldstein A (1987) Binding selectivity profiles for ligands of multiple receptor types: focus on opioid receptors. Trends Pharmacol Sci 8:456–460
Griebel G, Belzung C, Perrault G, Sanger DJ (2000) Differences in anxiety-related behaviors and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology 148:164–170
Holmes A (2001) Targeted gene mutation approaches to the study of anxiety-like behavior in mice. Neurosci Biobehav Rev 25:261–273
Holmes A, Wrenn CC, Harris AP, Thayer KE, Crawley JN (2002) Behavioral profiles of inbred strains on novel olfactory, spatial and emotional tests for reference memory in mice. Genes Brain Behav 1:55–69
Homanics GE, Quinlan JJ, Firestone LL (1999) Pharmacologic and behavioral responses of inbred C57BL/6J and strain 129/SvJ mouse lines. Pharmacol Biochem Behav 63:21–26
Kachaturian H, Lewis ME, Schafer MK-H, Watson SJ (1985) Anatomy of the CNS opioid systems. Trends Neurosci 8:111–119
Kang W, Wilson SP, Wilson MA (1999) Overexpression of proenkephalin in the amygdala potentiates the anxiolytic effects of benzodiazepines. Neuropsychopharmacology 22:77–88
Kieffer BL, Gaveriaux-Ruff C (2002) Exploring the opioid system by gene knockout. Prog Neurobiol 66:285–306
Konig M, Zimmer AM, Steiner H, Holmes PV, Crawley JN, Brownstein MJ, Zimmer AE (1996) Pain responses, anxiety and aggression in mice deficient in pre-proenkephalin. Nature 383:535–538
Lee C, Rodgers RJ (1990) Antinociceptive effects of elevated plus-maze exposure: influence of opiate receptor manipulations. Psychopharmacology 102:507–513
Logue SF, Owen EH, Rasmussen DL, Wehner JM (1997) Assessment of locomotor activity, acoustic and tactile startle, and prepulse inhibition in inbred mouse strains and F1 hybrids: implications of genetic background for single gene and quantitative trait loci analyses. Neuroscience 80:1075–1086
Mansour A, Fox CA, Akil H, Watson SJ (1995) Opioid receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18:22–29
Marco EM, Llorente R, Perez-Alvarez L, Moreno E, Guaza C, Viveros MP (2005) The κ-opioid receptor is involved in the stimulating effect of nicotine on adrenocortical activity but not in nicotine induced anxiety. Behav Brain Res 163:212–218
Marin S, Marco E, Biscaia M, Fernandez B, Rubio M, Guaza C, Schmidhammer H, Viveros MP (2003) Involvement of the κ-opioid receptor in the anxiogenic-like effect of CP 55,940 in male rats. Pharmacol Biochem Behav 74:649–656
Mas Nieto M, Guen SLE, Kieffer BL, Roques BP, Noble F (2005) Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors. Neuroscience 135:305–313
McIlwain KL, Merriweather MY, Yuva-Paylor LA, Paylor R (2001) The use of behavioral test batteries: effects of training history. Physiol Behav 73:705–717
Miczek KA, Thompson ML (1984) Analgesia resulting from defeat in a social confrontation: the role of endogenous opioids in brain. In: Bandler RJ (ed) Modulation of sensorimotor activity during altered behavioral states. AR Liss, New York, pp 431–456
Millan MJ (2003) The neurobiology and control of anxious states. Prog Neurobiol 70:83–244
Mogil JS, Wilson SG (1997) Nociceptive and morphine antinociceptive sensitivity of 129 and C57BL/6J inbred mouse strains: implications for transgenic knock-out studies. Eur J Pain 1:293–297
Mogil JS, Wilson SG, Bon K, Lee SE, Chung K, Raber P, Pieper JO, Hain HS, Belknap JK, Hubert L, Elmer GI, Chung JM, Devor M (1999) Heritability of nociception I: responses of 11 inbred mouse strains on 12 measures of nociception. Pain 80:67–82
Muraki T, Oike N, Shibata Y, Nomoto T (1991) Analgesia effects of μ- and κ-opioid agonists in beige and CXBK mice. J Pharm Pharmacol 43:210–212
Nelson RJ, Young KA (1998) Behavior in mice with targeted disruption of single genes. Neurosci Biobehav Rev 22:453–462
Ohl F (2005) Animal models of anxiety. In: Handbook of experimental pharmacology (Anxiety and anxiolytic drugs), vol 169, pp 35–69
Oliverio A, Castellano C (1974) Genotype-dependent sensitivity and tolerance to morphine and heroin: dissociation between opiate-induced running and analgesia in the mouse. Psychopharmacologia 39:13–22
Paulus MP, Duwala SC, Ralph RJ, Mark AG (1999) Behavioral organization is independent of locomotor activity in 129 and C57 mouse strains. Brain Res 835:27–36
Pert A, DeWald A, Liao H, Sivit C (1979) Effects of opiates and opioid peptides on motor behaviors: sites and mechanisms of action. In: Usdin E, Bunney WE, Kline NS (eds) Endorphins in mental health research. MacMillian, London, pp 45–61
Phillips TJ, Hen R, Crabbe JC (1999) Complications associated with genetic background effects in research using knockout mice. Psychopharmacology 147:5–7
Portoghese PS, Lipowski AW, Takemori AE (1987) Bi-naltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci 40:1287–1292
Portoghese PS, Sultana M, Takemori AE (1988) Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146:185–186
Privette TH, Terrian DM (1995) Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze. Psychopharmacology 118:444–450
Ragnauth A, Schuller AGP, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci U S A 98:1958–1963
Reggiani A, Battaini F, Kobayashi H, Spano P, Trabucchi M (1980) Genotype-dependent sensitivity to morphine: role of different opiate receptor populations. Brain Res 189:289–294
Rodgers RJ (1997) Animal models of ‘anxiety’: where next? Behav Pharmacol 8:477–496
Rodgers RJ (2001) Anxious genes, emerging themes. Behav Pharmacol 12:471–476
Rodgers RJ, Randall JI (1988) Environmentally induced analgesia: situational factors, mechanisms and significance. In: Rodgers RJ, Cooper SJ (eds) Endorphins, opiates and behavioural processes. Wiley, Chichester, pp 107–142
Rodgers RJ, Boullier E, Chatzimichalaki P, Cooper GD, Shorten A (2002a) Contrasting phenotypes of C57BL/6JOlaHsd, 129S2/SvHsd and 129/SvEv mice in two exploration-based tests of anxiety-related behaviour. Physiol Behav 77:301–310
Rodgers RJ, Davies B, Shore R (2002b) Absence of anxiolytic response to chlordiazepoxide in two common background strains exposed to the elevated plus-maze: importance and implications of behavioural baseline. Genes Brain Behav 1:242–251
Rodgers RJ, Evans PM, Murphy A (2005) Anxiogenic profile of AM-251, a selective cannabinoid CB1 receptor antagonist, in plus-maze-naïve and plus-maze-experienced mice. Behav Pharmacol 16:405–413
Rogers DC, Jones DNC, Nelson PR, Jones CM, Quilter CA, Robinson TL, Hagan JJ (1999) Use of SHIRPA and discriminant analysis to characterise marked differences in the behavioural phenotype of six inbred mouse strains. Behav Brain Res 105:207–217
Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective δ-opioid agonist, in behavioral models in rodents. J Pharm Sci 95:374–380
Sasaki K, Fan L-W, Tien L-T, Ma T, Loh HH, Ho IK (2002) The interaction of morphine and γ-aminobutyric acid (GABA)ergic systems in anxiolytic behavior: using μ-opioid receptor knockout mice. Brain Res Bull 57:689–694
Silva RH, Frussa-Filho R (2002) Naltrexone potentiates both amnestic and anxiolytic effects of chlordiazepoxide in mice. Life Sci 72:721–730
Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp JJ (1997) Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nature genetics 16:19–27
Sugita S, North RA (1993) Opioid actions on neurons of lateral amygdala in vivo. Brain Res 612:151–155
Tang X, Sanford LD (2005) Home cage activity and activity-based measures of anxiety in 129P3/J, 129X1/SvJ and C57BL/6J mice. Physiol Behav 84:105–115
Tarantino LM, Gould TJ, Druham JP, Bucan M (2000) Behavior and mutagenesis screens: the importance of baseline analysis of inbred strains. Mamm Genome 11:555–564
Thompson WR (1953) The inheritance of behavior: behavioral differences in fifteen mouse strains. Can J Psychol 7:145–155
Treit D, Menard J, Royan C (1993) Anxiogenic stimuli in the elevated plus-maze. Pharmacol Biochem Behav 44:463–469
Trullas R, Skolnick P (1993) Differences in fear motivated behaviors among inbred mouse strains. Psychopharmacology 111:323–331
Tsuda M, Suzuki T, Misawa M, Nagase H (1996) Involvement of the opioid system in the anxiolytic effect of diazepam in mice. Eur J Pharmacol 307:7–14
Vaccarino AL, Plamondon H, Melzack R (1992) Analgesic and aversive effects of naloxone in BALB/c mice. Exp Neurol 117:216–218
van Abeelen JHF, van Heuvel CM (1982) Behavioural responses to novelty in two inbred mouse strains after intrahippocampal naloxone and morphine. Behav Brain Res 5:199–207
van Abeelen JHF, van Nies JHM (1983) Effects of intrahippocampally injected naloxone and morphine upon behavioural responses to novelty in mice from two selectively bred lines. Psychopharmacology 81:232–235
van Gaalen MM, Steckler T (2000) Behavioural analysis of four mouse strains in an anxiety test battery. Behav Brain Res 115:95–106
Voikar V, Koks S, Vasar E, Rauvala H (2001) Strain and gender differences in the behavior of mouse lines commonly used in transgenic studies. Physiol Behav 72:271–281
Ward SJ, Portoghese PS, Takemori AE (1982) Pharmacological characterization in vivo of the novel opiate, beta-funaltrexamine. J Pharmacol Exp Ther 220:494–498
Weiss SM (1995) Pharmacological and behavioural examination of the defensive reactions of laboratory mice to the calls of the Tawny Owl. Ph.D. Thesis, University of Leeds
Acknowledgement
The authors are grateful to Professor Jorgen Scheel-Kruger (Neurosearch A/S, Copenhagen) for insightful comments that stimulated the present series of experiments.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rodgers, R.J., Augar, R., Berryman, N. et al. Atypical anxiolytic-like response to naloxone in benzodiazepine-resistant 129S2/SvHsd mice: role of opioid receptor subtypes. Psychopharmacology 187, 345–355 (2006). https://doi.org/10.1007/s00213-006-0435-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-006-0435-y